Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib

Ítems similars

• Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
  per: Green, John A.
  Publicat: (2018)
• Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI
  per: Okuma, Yusuke, et al.
  Publicat: (2017)
• Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
  per: Passiglia, Francesco, et al.
  Publicat: (2018)
• First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
  per: Jeong, Byeong-Ho, et al.
  Publicat: (2018)
• Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer
  per: Liam, Chong-Kin
  Publicat: (2019)